Idoven1903, S.L.

Based in Spain, Idoven 1903, S. L. is a healthcare technology company that specializes in AI-driven cardiology solutions, aiding clinicians in diagnosing and managing cardiovascular diseases effectively. Idoven 1903, S.

L. was founded in 2018 in Madrid, Spain, and focuses on providing advanced cardiology services. The company has secured a total funding of EUR 12. 000 mn across multiple rounds, with the latest being a GRANT of EUR 6.

500 mn received on September 5, 2023, from the European Innovation Council. The founders, Iñigo Juantegui, José Castellano, and Manuel Breysse, have a commitment to improving cardiovascular care through innovative technology. Idoven delivers an innovative cardiology-as-a-service platform that utilizes artificial intelligence to support clinicians in the identification, triage, and diagnosis of cardiovascular conditions. The core product offerings include advanced ECG interpretation and analysis, enabling the rapid and accurate detection of arrhythmias and cardiac patterns.

This technology integrates seamlessly with Home Monitoring and Electronic Health Record systems, providing efficient patient management at scale. Additionally, Idoven offers disease risk stratification through ECG-based biomarkers to identify high-risk patients and comprehensive preventative screening programs aimed at enhancing employee health and wellbeing, serving healthcare providers, pharmaceutical firms, and medical device companies in Europe and the United States. Idoven operates on a business-to-business (B2B) model, primarily engaging with healthcare providers and life sciences companies through partnerships and subscription-based agreements. The revenue for the most recent year, 2020, was EUR 63,231.

20 with an EBITDA of EUR -102,516. 40. Revenue generation occurs through the provision of its AI-driven ECG analysis services, which typically involve ongoing subscriptions for access to its platform and associated analytics. Clients benefit from services such as continuous remote ECG monitoring and detailed medical-grade reports generated by proprietary algorithms and cardiologists, with pricing plans tailored to the specific needs of large healthcare systems or individual practices.

In September 2023, Idoven1903, S. L. raised EUR 6. 500 mn in venture funding, co-led by Insight Partners and Northzone, aimed at business expansion and further product development.

The company plans to enhance its AI-driven services and expand its presence in new geographic regions to improve cardiovascular care globally.